Fennec Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update
~ 2026 Second Quarter Net Product Sales of $17.1 Million, Up 78% Year over Year ~ ~ 2026 Second Quarter Non-GAAP Adjusted EBITDA of $2.8 Million ~ ~ Record PEDMARK® Demand Carried into Third Quarter 2026 as Field Sales Expansion Efforts Continue to Validate Commercial Growth Strategy ~ ~ Real-World Evidence Presented at ASCO 2026 Reinforced that […]
We haven't written up this one. Financial Post has the full story — the link below goes straight to it.
